OncoSignal
Live from Open Targets Platform, fetched 2026-11-12 00:08 UTC. Every row links to its source record.

PRKAR1A protein kinase cAMP-dependent type I regulatory subunit alpha

ENSG00000108946 · protein coding · Open Targets profile

Regulatory subunit of the cAMP-dependent protein kinases involved in cAMP signaling in cells. {ECO:0000269|PubMed:16491121, ECO:0000269|PubMed:20215566, ECO:0000269|PubMed:26405036, ECO:0000269|PubMed:35977512}.

In 11 of 15 cancers, the evidence for PRKAR1A comes mainly from mutations found in tumours

Each row is a cancer, strongest overall evidence first. The two dots show how strong the inherited (germline) and tumour-mutation (somatic) evidence is; the line between them is the gap.

Inherited (germline) variantsMutations in tumours (somatic)
00.250.50.751familial atrial myxomafamilial atrial myxomafamilial atrial myxoma: germline 0.77hereditary neoplastic syndromehereditary neoplastic syndromehereditary neoplastic syndrome: germline 0.89endocrine gland neoplasmendocrine gland neoplasmmalignant endocrine neoplasmmalignant endocrine neoplasmadrenal cortex carcinomaadrenal cortex carcinomaadrenal cortex carcinoma: somatic 0.55medulloblastomamedulloblastomamedulloblastoma: somatic 0.47thyroid gland follicular carcinomathyroid gland follicular carcinomathyroid gland follicular carcinoma: somatic 0.61myxomamyxomamyxoma: somatic 0.61thyroid gland papillary carcinomathyroid gland papillary carcinomathyroid gland papillary carcinoma: somatic 0.61blue nevusblue nevusblue nevus: somatic 0.61Chordoid MeningiomaChordoid MeningiomaChordoid Meningioma: somatic 0.61Transitional MeningiomaTransitional MeningiomaTransitional Meningioma: somatic 0.61thyroid gland oncocytic adenomathyroid gland oncocytic adenomathyroid gland oncocytic adenoma: somatic 0.61Thyroid Gland Oncocytic Follicular Carc…Thyroid Gland Oncocytic Follicular CarcinomaThyroid Gland Oncocytic Follicular Carcinoma: somatic 0.61follicular variant thyroid gland papill…follicular variant thyroid gland papillary carcinomafollicular variant thyroid gland papillary carcinoma: somatic 0.61

Scores run from 0 (no evidence) to 1 (strongest). A missing dot at 0 means Open Targets holds no evidence of that kind. Source: Open Targets Platform, fetched live.

Tractability

Small molecule
Structure with Ligand
Antibody
UniProt loc high conf, GO CC med conf
PROTAC
Database Ubiquitination, Half-life Data

gnomAD loss of function constraint: o/e 0.05770599842071533 (upper bound 0.14914000034332275). Low values mean loss of function is poorly tolerated, a safety flag for inhibition.

Who runs trials of these drugs

No named investigators on registry trials of PRKAR1A's approved or late-stage drugs in the last three years.

No terminated, withdrawn or suspended trials of PRKAR1A's drugs are registered

All 0 drugs and clinical candidates as a table

Each drug, stage and indication links to its Open Targets record, where the trials and approvals behind it are listed. Salt forms (for example a mesylate) are listed as Open Targets records them, as separate entries.

DrugTypeHighest stageIndicationsSource records
No drugs or clinical candidates recorded.